(Q33501194)

27 July 2017

title

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy (English)

1 reference

27 July 2017

Mainwaring PN

1

1 reference

27 July 2017

Nicolson MC

2

1 reference

27 July 2017

Hickish T

3

1 reference

27 July 2017

Penson R

4

1 reference

27 July 2017

Joel S

5

1 reference

27 July 2017

Slevin M

6

1 reference

27 July 2017

Smith IE

7

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

British Journal of Cancer

27 July 2017

published in

1 reference

27 July 2017

volume

76

1 reference

27 July 2017

issue

12

1 reference

27 July 2017

page(s)

1636-1639

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1997.609

27 July 2017

exact match

0 references

cites work

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Reporting results of cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Clinical trials with the topoisomerase I inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228211

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

21 June 2018

1 reference

PubMed

12 December 2020

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/BJC.1997.609

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference